drugset
Drugs / SB-728-T
last change Feb 2024 re-read 3 minutes ago

SB-728-T

Cell therapy targets CCR5

Developed for
HIV infectious disease
Investigated by
Sangamo Therapeutics · Case Western Reserve University · University of California, San Francisco · University of Cincinnati

Trials 4

today NCT03666871 · Ph 1/2 NCT01543152 · Ph 1/2 NCT01252641 · Ph 1/2 NCT01044654 · Ph 1
201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT01044654 Dec 2009 → Dec 2014 HIV infectious disease Sangamo Therapeutics Completed No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT03666871 Jun 2019 → Jan 2024 HIV infectious disease University of Cincinnati Completed No outcome recorded
Phase 1/2 NCT01543152 Dec 2011 → Jul 2017 HIV infectious disease Sangamo Therapeutics Completed No outcome recorded
Phase 1/2 NCT01252641 Nov 2010 → Dec 2014 HIV infectious disease Sangamo Therapeutics Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as SB-728-T ClinicalTrials.gov intervention name — accepted as the source's own label NCT01543152 ↗
3

NCT01044654 ↗

NCT01252641 ↗

NCT03666871 ↗
Modality Cell therapy “Additional genetically modified cells are manufactured and then re-infused back into you.” NCT01044654 ↗
Route Intravenous “single intravenous infusion of 0.5 to 3.0 x 1010 SB-728-T” NCT01044654 ↗
Target CCR5 “removing the CCR5 gene from the surface of the CD4+ T cell” NCT01044654 ↗